Supercharged immune cells take on deadly brain tumors
NCT ID NCT07551336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment uses a patient's own immune cells (NK cells) that have been engineered in a lab to better recognize and attack tumor cells. The cells are delivered directly into the brain. The study aims to find a safe dose and see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dual-targeting CAR-NK cells (immune cells engineered to recognize and attack brain tumor cells)
What this could lead to
If this works, it could point toward a new treatment option for people with recurrent glioblastoma, a type of brain cancer that is very hard to treat.
What could go wrong
This is a very early (phase 1) and small trial (36 people). The main goal is safety, not effectiveness. It may not work, and there are risks like severe immune reactions or brain swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••